Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity

Diabetes, Metabolic Syndrome and Obesity

Volumn 6, Issue , 2013, Pages 131-139

  Shin, Jin Hee ^a   Gadde, Kishore M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antiobesity drugs; Combination drug; Obesity; Phentermine; Qsymia; Topiramate; Weight loss

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; TOPIRAMATE; TRIACYLGLYCEROL;

ANXIETY; ARTICLE; ATTENTION DISTURBANCE; BLURRED VISION; COGNITIVE DEFECT; CONCENTRATION LOSS; CONSTIPATION; DEPRESSION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; HEADACHE; HEART PALPITATION; HEART RATE; HUMAN; HYPERTENSION; INSOMNIA; IRRITABILITY; LANGUAGE DISABILITY; LOW DRUG DOSE; MEMORY DISORDER; MENTAL DISEASE; MIGRAINE; MOOD CHANGE; MORNING DOSAGE; NAUSEA; NERVOUSNESS; OBESITY; PARESTHESIA; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RECOMMENDED DRUG DOSE; SEIZURE; SIDE EFFECT; SLEEP DISORDERED BREATHING; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TREATMENT PLANNING; WEIGHT REDUCTION; XEROSTOMIA;

EID: 84876031270     PISSN: 11787007     EISSN: None     Source Type: Journal    
DOI: 10.2147/DMSO.S43403     Document Type: Article

References (57)

1. World Health Organization. Obesity and overweight [webpage on the Internet]. Geneva: World Health Organization; 2012. Available from: http://www.who.int/mediacentre/factsheets/fs311/en/index.html. Accessed March 25, 2013.
2. James WP. The epidemiology of obesity: the size of the problem. J Intern Med. 2008;263(4):336-352.
3. Haslam DW, James WP. Obesity. Lancet. 2005;366(9492):1197-1209.
4. Overweight, obesity, and health risk. National Task Force on the Prevention and Treatment of Obesity. Arch Intern Med. 2000;160(7):898-904.
5. Kramer FM, Jeffery RW, Forster JL, Snell MK. Long-term follow-up of behavioral treatment for obesity: patterns of weight regain among men and women. Int J Obes. 1989;13(2):123-136.
6. Ayyad C, Andersen T. Long-term efficacy of dietary treatment of obesity: a systematic review of studies published between 1931 and 1999. Obes Rev. 2000;1(2):113-119.
7. Gadde KM, Allison DB. Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks. Circulation. 2006;114(9):974-984.
8. Taylor D. Withdrawal of Rimonabant - walking the tightrope of 21st century pharmaceutical regulation? Curr Drug Saf. 2009;4(1):2-4.
9. Williams G. Withdrawal of sibutramine in Europe. BMJ. 2010;340:c824.
10. Leblanc ES, O'Connor E, Whitlock EP, Patnode CD, Kapka T. Effectiveness of primary care-relevant treatments for obesity in adults: a systematic evidence review for the US Preventive Services Task Force. Ann Intern Med. 2011;155(7):434-447.
11. Foreyt JP, Goodrick GK, Gotto AM. Limitations of behavioral treatment of obesity: review and analysis. J Behav Med. 1981;4(2):159-174.
12. Wadden TA, Sternberg JA, Letizia KA, Stunkard AJ, Foster GD. Treatment of obesity by very low calorie diet, behavior therapy, and their combination: a five-year perspective. Int J Obes. 1989; 13 Suppl 2:39-46.
13. Gadde KM, Kopping MF, Wagner HR 2nd, Yonish GM, Allison DB, Bray GA. Zonisamide for weight reduction in obese adults. Arch Intern Med. 2012;172(20):1557-1564.
14. Methods for voluntary weight loss and control. NIH Technology Assessment Conference Panel. Consensus Development Conference, March 30 to April 1, 1992. Ann Intern Med. 1993;119(7 Pt 2):764-770.
15. Long-term pharmacotherapy in the management of obesity. National Task Force on the Prevention and Treatment of Obesity. JAMA. 1996;276(23):1907-1915.
16. Gadde KM, Allison DB. Combination pharmaceutical therapies for obesity. Expert Opin Pharmacother. 2009;10(6):921-925.
17. Gadde KM, Allison DB. Combination therapy for obesity and metabolic disease. Curr Opin Endocrinol Diabetes Obes. 2009;16(5):353-358.
18. Dickerson LM, Carek PJ. Pharmacotherapy for the obese patient. Prim Care. 2009;36(2):407-415.
19. Qsymia™ (phentermine and topiramate extended-release) [prescribing information]. Mountain View, CA: VIVIUS, Inc; 2012.
20. Rothman RB, Baumann MH. Appetite suppressants, cardiac valve disease and combination pharmacotherapy. Am J Ther. 2009;16(4):354-364.
21. Alexander M, Rothman RB, Baumann MH, Endres CJ, Brasić JR, Wong DF. Noradrenergic and dopaminergic effects of (+)-amphetamine-like stimulants in the baboon Papio anubis. Synapse. 2005;56(2):94-99.
22. Adipex-P (phenteramine) [prescribing information]. Philadelphia, PA: Teva Pharmaceuticals USA, Inc; 2012.
23. Verrotti A, Scaparrotta A, Agostinelli S, Di Pillo S, Chiarelli F, Grosso S. Topiramate-induced weight loss: a review. Epilepsy Res. 2011;95(3):189-199.
24. Bray GA, Hollander P, Klein S, et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res. 2003;11(6):722-733.
25. Astrup A, Caterson I, Zelissen P, et al. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes Res. 2004;12(10):1658-1669.
26. Rosenstock J, Hollander P, Gadde KM, Sun X, Strauss R, Leung A; for OBD-202 Study Group. A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients. Diabetes Care. 2007;30(6):1480-1486.
27. Stenlöf K, Rössner S, Vercruysse F, Kumar A, Fitchet M, Sjöström L; OBDM-003 Study Group. Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes. Diabetes Obes Metab. 2007;9(3): 360-368.
28. Eliasson B, Gudbjörnsdottir S, Cederholm J, Liang T, Vercruysse F, Smith U. Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial. Int J Obes (Lond). 2007;31(7):1140-1147.
29. Tonstad S, Tykarski A, Weissgarten J, et al. Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension. Am J Cardiol. 2005;96(2):243-251.
30. Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M; OBES-002 Study Group. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord. 2004;28(11):1399-1410.
31. Toplak H, Hamann A, Moore R, et al. Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Int J Obes (Lond). 2007;31(1):138-146.
32. Richard D, Ferland J, Lalonde J, Samson P, Deshaies Y. Influence of topiramate in the regulation of energy balance. Nutrition. 2000;16(10): 961-966.
33. Richard D, Picard F, Lemieux C, Lalonde J, Samson P, Deshaies Y. The effects of topiramate and sex hormones on energy balance of male and female rats. Int J Obes Relat Metab Disord. 2002;26(3): 344-353.
34. Picard F, Deshaies Y, Lalonde J, Samson P, Richard D. Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats. Obes Res. 2000;8(9):656-663.
35. Ben-Menachem E, Axelsen M, Johanson EH, Stagge A, Smith U. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res. 2003;11(4):556-562.
36. Tremblay A, Chaput JP, Bérubé-Parent S, et al. The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension. Eur J Clin Pharmacol. 2007;63(2):123-134.
37. Khazaal Y, Zullino DF. Topiramate-induced weight loss is possibly due to the blockade of conditioned and automatic processes. Eur J Clin Pharmacol. 2007;63(9):891-892; author reply 893.
38. McElroy SL, Arnold LM, Shapira NA, et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry. 2003;160(2):255-261.
39. Turenius CI, Htut MM, Prodon DA, et al. GABA(A) receptors in the lateral hypothalamus as mediators of satiety and body weight regulation. Brain Res. 2009;1262:16-24.
40. De Simone G, Di Fiore A, Supuran CT. Are carbonic anhydrase inhibitors suitable for obtaining antiobesity drugs? Curr Pharm Des. 2008;14(7):655-660.
41. Dodgson SJ, Shank RP, Maryanoff BE. Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia. 2000;41(Suppl 1): S35-S39.
42. Dahl H, Norskov K, Peitersen E, Hilden J. Zinc therapy of acetazolamide-induced side-effects. Acta Ophthalmol. 1984;62: 739-745.
43. Husum H, Van Kammen D, Termeer E, Bolwig G, Mathé A. Topiramate normalizes hippocampal NPY-LI in flinders sensitive line 'depressed' rats and upregulates NPY, galanin, and CRH-LI in the hypothalamus: implications for mood-stabilizing and weight loss-inducing effects. Neuropsychopharmacology. 2003;28(7): 1292-1299.
44. Wilkes JJ, Nelson E, Osborne M, Demarest KT, Olefsky JM. Topiramate as an insulin-sensitizing compound in vivo with direct effects on adipocytes in female ZDF rats. Am J Physiol Endocrinol Metab. 2005;288(3):E617-E624.
45. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116(7):1784-1792.
46. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341-1352.
47. Bialer M, Doose DR, Murthy B, et al. Pharmacokinetic interactions of topiramate. Clin Pharmacokinet. 2004;43(12):763-780.
48. Food and Drug Administration. July 15, 2010, Advisory Committee Meeting for Phentermine/Topiramate (Qnexa). Silver Spring, MD: Division of Metabolism and Endocrinology Products (DMEP) Office of Drug Evaluation II Center for Drug Evaluation and Research, US Food and Drug Administration; 2010. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommitee/UCM218824.pdf. Accessed March 25, 2013.
49. Gadde KM, Yonish GM, Foust MS, et al. A 24-week randomized controlled trial of VI-0521, a combination weight loss therapy, in obese adults [abstract]. Obes Res. 2006;14:A17.
50. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20(2):330-342.
51. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95(2):297-308.
52. Winslow DH, Bowden CH, DiDonato K, McCullough PA. A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phetermine/topiramate for the treatment of obstructive sleep apnea in obese adults. Sleep. 2012;35(11):1529-1539.
53. Hunt S, Russell A, Smithson WH, et al; UK Epilepsy and Pregnancy Register. Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology. 2008;71(4):272-276.
54. Food and Drug Administration. Clinical Briefing Document, Endocrine and Metabolic Drugs Advisory Committee Meeting, February 22, 2012. New Drug Application 22580: VI-052 Qnexa (phentermine/topiramate). Silver Spring, MD: Food and Drug Administration; 2012 Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM292315.pdf. Accessed March 25, 2013.
55. White WB. Heart rate and the rate-pressure product as determinants of cardiovascular risk in patients with hypertension. Am J Hypertens. 1999;12(2 Pt 2):50S-55S.
56. LaRoche SM, Helmers SL. The new antiepileptic drugs: scientific review. JAMA. 2004;291(5):605-614.
57. Wenzel RG, Schwarz K, Padiyara RS. Topiramate for migraine prevention. Pharmacotherapy. 2006;26(3):375-387.